Cytokinetics(US:CYTK) Prnewswire·2025-10-23 12:45Core Points - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated regarding potential lead plaintiff appointments in a class action lawsuit related to misleading statements about the New Drug Application (NDA) for aficamten [1][2] - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, during which shareholders are encouraged to register for participation [2] - Allegations include that Cytokinetics misrepresented the timeline for FDA approval and failed to disclose risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), leading to inflated stock prices and subsequent losses for investors when the truth was revealed [1] Company Specifics - Cytokinetics is facing legal scrutiny for allegedly making materially false and misleading statements regarding its NDA submission process for aficamten, which is critical for its market position [1] - The company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, which could have significant implications for its regulatory approval process [1] Legal Context - The Gross Law Firm is recognized for its commitment to protecting investor rights and seeks recovery for those who suffered losses due to misleading corporate practices [3] - Shareholders are advised to register by November 17, 2025, to be included in the monitoring of the case's progress [2]